A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place this May in Boston (21-23)! The ADC payload landscape is shifting rapidly.

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

and Biohaven’s next-generation ADC conjugation and payload platform technologies. Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus ...

Tubulis has dosed the first subject in the multicentre Phase I/IIa 5-STAR 1-01 trial to clinically evaluate its second drug ...

TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based on Tubulis’ proprietary P5 conjugation technology, which has demonstrated effective and durable responses ...

TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite ...

GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Food and Drug Administration (FDA ...

Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based ...

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...